Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma

Abstract Background In the Republic of Korea, only lenalidomide, bortezomib, ixazomib, and thalidomide monotherapy are available as maintenance therapy post-autologous stem cell transplantation (ASCT). Methods To determine whether maintenance therapy confers a survival benefit in the real world, we...

Full description

Saved in:
Bibliographic Details
Main Authors: Ka-Won Kang, Dae Sik Kim, Se Ryeon Lee, Mi Hwa Heo, Hyeon-Seok Eom, Jongheon Jung, Ji Hyun Lee, Sung-Hyun Kim, Youngil Koh, Chang-Ki Min, Seung Shin Lee, Sung-Nam Lim, Ho-Young Yhim, Myung-won Lee, Je-Jung Lee, Sung-Hoon Jung, Soo-Mee Bang, Kihyun Kim, the Korean Multiple Myeloma Working party [KMMWP]
Format: Article
Language:English
Published: BMC 2025-02-01
Series:BMC Cancer
Subjects:
Multiple myeloma
Autologous stem cell transplantation
Maintenance
Thalidomide
Lenalidomide
Bortezomib
Online Access:https://doi.org/10.1186/s12885-025-13518-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12885-025-13518-0

Similar Items